Service de Néphrologie, Université Denis Diderot-Paris VII, Hôpital Saint Louis, Paris, France.
Am J Transplant. 2010 Oct;10(10):2263-9. doi: 10.1111/j.1600-6143.2010.03258.x. Epub 2010 Sep 14.
Kidney transplantation is now considered as a reasonable option for HIV-infected patients with end-stage renal disease. We describe here a retrospective study conducted in five transplantation centers in Paris. Twenty-seven patients were included. Immunosuppressive protocol associated an induction therapy and a long-term treatment combining mycophenolate mofetil, steroids and either tacrolimus or cyclosporine. All the patients had protocol biopsies at 3 months and 1 year. Patient's survival was 100% at 1 year and 98% at 2 years. Graft survival at 1 and 2 years is 98% and 96% at 1 and 2 years, respectively. The mean glomerular filteration rate values at 12 and 24 months were 60.6 mL/min/1.73 m² (range 23-98) and 65.4 mL/min/1.73 m² (range 24-110), respectively. Acute cellular rejection was diagnosed in four cases (15%). Because of high trough levels of calcineurin inhibitor, protease-inhibitor therapies were withdrawn in 11 cases. HIV disease progression was not observed. One patient developed B-cell lymphoma. In conclusion, our study confirms the safety of renal transplantation in HIV-infected patients with few adverse events and a low incidence of acute rejection.
肾移植现在被认为是 HIV 感染且终末期肾病患者的合理选择。我们在此描述了在巴黎的五家移植中心进行的一项回顾性研究。共纳入 27 例患者。免疫抑制方案包括诱导治疗和长期治疗,联合使用霉酚酸酯、类固醇和他克莫司或环孢素。所有患者均在 3 个月和 1 年时进行了方案活检。1 年时患者存活率为 100%,2 年时为 98%。1 年和 2 年时移植物存活率分别为 98%和 96%。12 个月和 24 个月时的平均肾小球滤过率分别为 60.6 mL/min/1.73 m²(范围 23-98)和 65.4 mL/min/1.73 m²(范围 24-110)。有 4 例(15%)诊断为急性细胞性排斥反应。由于钙调神经磷酸酶抑制剂的谷浓度较高,11 例患者停用了蛋白酶抑制剂治疗。未观察到 HIV 疾病进展。1 例患者发生 B 细胞淋巴瘤。总之,我们的研究证实了肾移植在 HIV 感染患者中的安全性,不良事件较少,急性排斥反应发生率较低。